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ABSTRACT  
Objective: The main purpose of this study was to develop a simple, precise, rapid and accurate method for the quantification of cardiazol in human 
plasma. 
Methods: Chromatography was achieved on Discovery C18, 50 × 2.1 mm, 5 μm column. Samples were chromatographed in a gradient mode (eluent 
A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). The initial content of the eluent B of 8%, which 
increases linearly to 1.0 min to 100%, is maintained up to 1.5 min and returned to the original 8% to 1.51 min. The mobile phase was delivered at a 
flow rate of 0.400 ml/min into the mass spectrometer ESI chamber. The sample volume was 300 μl.  
Results: The total chromatographic run time was 2.5 min and the elution of cardiazol and IS (difenoconazole) occurred at ~2.15 and 1.98 min, 
respectively. A linear response function was established at 1-100 ng/ml for cardiazol and difenoconazole in human plasma. The % mean recovery 
for cardiazol in LQC, MQC and HQC was 102.8 %, 100.3 % and 95.9 %. The lowest concentration with the RSD<20% was taken as LLOQ and was 
found to be 1.10 ng/ml for cardiazol. The % accuracy of LLOQ samples prepared with the different biological matrix lots was found 109.7 %, which 
were found within the range of 80.00-120.00 % for the seven different plasma lots. % CV for LLOQ samples was observed as 11.9 %, which are 
within 20.00% of the acceptance criteria. 
The within-run coefficients of variation ranged between 0.311 % and 0.601 % for cardiazol. The within-run percentages of nominal concentrations 
ranged between 99.80 % and 100.41 % for cardiazol. The between-run coefficients of variation ranged between 0.332 % and 0.615 % for cardiazol. 
The between-run percentages of nominal concentrations ranged between 98.18 % and 101.21 % for cardiazol. 
Conclusion: A rapid method was developed for simultaneous determination of cardiazol in human plasma. The method was strictly validated 
according to the ICH guidelines. Acquired results demonstrate that the proposed strategy can be effortlessly and advantageously applied for routine 
examination of cardiazol in human plasma.  
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Bioanalytical methodology is the founder of the study of 
bioequivalence and therapeutic drug monitoring, so the main focus 
in the study of pharmacokinetics and bioequivalence should be given 
to the development of bioanalytical methods of analysis. 
Bioanalytical method validation employed for the quantitative 
determination of drugs and their metabolites in biological fluids 
plays a significant role in the evaluation and interpretation of 
bioavailability, bioequivalence, pharmacokinetic, and toxicokinetic 
study data [1]. These studies generally support regulatory filings. 
The quality of these studies is directly related to the quality of the 
underlying bioanalytical data.  
 
 
Fig. 1: Chemical structure of cardiazol 
Cardiazol (fig. 1) (hydrobromide [3-Allyl-4-(41-methoxyphenyl)-3H-
thiazole-2-ylidene]-(32
MATERIALS AND METHODS 
-trifluoromethylphenyl) amine)–the original 
newly synthesized cardioprotective, which, in addition to the 
cardioprotective effect, also exhibits hypolipidemic, anti-
inflammatory, analgesic and antioxidant activity [2]. This indicates 
the promise of this substance for further preclinical studies. 
Therefore, it was thought desirable to develop a simple, accurate, 
cheap and fast procedure that could be applied for the 
determination of cardiazol in human plasma, this study performed 
assay validations as per guidelines [3-5]. While this method with 
validation details was economical and applied for pharmacokinetic 
studies of cardiazol. 
Chemicals and reagents 
Cardiazol (purity 98.5 %) was synthesized by us, difenoconazole 
(Internal Standard) (purity 98.8 %) was purchased from Moehs 
Catalana, S. L., Spain, Zhejiang Huahai Pharmaceutical Co., Ltd, КНР, 
EDQM–Council of Europe. HPLC grade acetonitrile and methanol 
were purchased from CHROMASOLV, HPLC grade formic acid was 
purchased from Fluka. All other chemicals and reagents were of 
analytical grade. Microcaps® disposable micropipettes (50 μl, 
catalog number: 1-000-0500) were purchased from Drummond 









EDTA) plasma sample was 
procured from Red Cross Society, Ukraine.  
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Instrumentation and chromatographic conditions 
A Shimadzu HT (Shimadzu, Japan) LC system equipped with 
degasser (DGU-14A), binary pump (LC-20ADXR) along with auto-
sampler (SIL-20AC HT) was used to inject 5 μl aliquots of the 
processed samples on Discovery C18, 50 × 2.1 mm, 5 μm column 
maintained at 25±1 °C. Samples were chromatographed in a gradient 
mode (eluent A (acetonitrile-water–formic acid, 5: 95: 0.1 v/v), 
eluent B (acetonitrile–formic acid, 100: 0.1 v/v)). Samples were 
chromatographed in gradient mode. The initial content of the eluent 
B of 8%, which increases linearly to 1.0 min to 100%, is maintained 
up to 1.5 min and returned to the original 8% to 1.51 min. The 
mobile phase was delivered at a flow rate of 0.400 ml/min into the 
mass spectrometer ESI chamber. Parameters of electrospray ionizer 
and MRM parameters are listed in table 1-2. The analytical data were 
processed by Analyst Software (version 1.5.2). 
 
Table 1: Parameters of ionizer electrospray 
S. No. Parameter Value 
1 Polarity Positive 
2 Nebulizer Gas (NEB, Gas 1) 15 
3 Curtain Gas (CUR) 8 
4 Collision Gas (CAD) 4 
5 IonSpray Voltage (IS) 5000 
6 Temperature (TEM) 400 
7 Turbo IonSpray Gas 8 
8 Horizontal Position 8.0 
9 Lateral Position 2.0 
 
Table 2: Multiple reaction monitoring (MRM) parameters 
ID Parent, m/z Daughter, m/z Time, ms DP, V EP, V CE, V CXP, V 
Cardiazol 391.018 360.1 40 46 11 35 20 




Cardiazil and IS were weighed accurately into volumetric flasks using 
an analytical microbalance. Approximately 1 mg/ml primary stock 
solutions of cardiazol and 1 mg/ml primary stock solutions of 
difenoconazole (IS) solutions were prepared in methanol. The stock 
solutions were stored at −20 °C, which was found to be stable for 1 mo. 
The stock solutions of cardiazol and difenoconazole were successively 
diluted with methanol and water to prepare secondary stocks and 
working solutions. Secondary stock solutions and working solutions 
were used to prepare calibration curve (CC) and quality control (QC) 
samples. Working stock solutions were stored at 4 °C for a week. 
Working stocks were used to prepare plasma calibration standards. A 
working IS solution (50 ng/ml) was prepared in acetonitrile: methanol 
(50:50 v/v). Blank human plasma was screened before spiking to 
ensure that it was free from endogenous interference at retention 
times of cardiazol and difenoconazole, respectively. Calibration 
standards’ samples (1-100 ng/ml for cardiazol and difenoconazole) 
were prepared by spiking the blank human K
Abbreviations: DP, declustering potential; FP, focusing potential; EP, entrance potential; CE, collision energy; CXP, collision cell exit potential 
2
A full validation according to the ICH guidelines was performed for 
the assay in K
EDTA plasma with 
appropriate concentration of cardiazol.  
Samples for the determination of precision and accuracy were 
prepared by spiking control human plasma in bulk with cardiazol at 
appropriate concentrations (for cardiazol 3.00 ng/ml low QC [LQC], 
30.00 ng/ml medium QC [MQC], and 75.00 ng/ml high QC [HQC]) 
and 120 μL plasma aliquots were distributed into different tubes. All 
the samples were stored at −80 °C±10 °C.  
Sample preparation 
A simple protein precipitation extraction method was followed for 
extraction of cardiazol at from human plasma. From the deep 
freezer, the required quantities of CC standards and QC samples 
were withdrawn. The samples were thawed at room temperature. 
To an aliquot of 100 μl plasma, 20 μl of IS was added. To this 
mixture, 300 μl of acetonitrile: methanol (50:50 v/v) was added and 
vortexed for 2 min, followed by centrifugation at 6000 rpm for 5 min 
at 4 °C. After centrifugation, approximately 50 μl supernatant was 
aliquoted into, respectively, labeled autosampler vials, which were 
later placed in the autosampler at 15 °C±4 °C. 10 μl of the sample 
was injected onto LC-MS/MS system for analysis. 
Method validation 
2EDTA human plasma. 
Specificity and selectivity 
The specificity of the method was evaluated by analyzing human plasma 
samples from different lots to investigate the potential interferences at 
the chromatographic peak region for cardiazol and IS. The acceptance 
criterion for the experiment was that should have<20% area response to 
that of the LLOQ level response in the same matrix. Two lots of 
hemolyzed plasma samples were also analyzed to ensure specificity 
against potential biological interferences. 
Linearity 
The points CC (1-100 ng/ml) were constructed by plotting the peak 
area ratio of analyte: IS against the nominal concentration of 
calibration standards in K2EDTA human plasma. Following the 
evaluation of different weighting factors, the results were fit into 
linear regression analysis using 1/X2 
The effect of human plasma constituents over the ionization of 
cardiazol and IS was determined by post-column infusion method to 
evaluate matrix effect. Briefly, an infusion pump delivers a constant 
amount of analyte into LC system outlet entering to mass 
spectrometer inlet. To follow the analyte signal, the mass 
spectrometer was operated in MRM mode. The human plasma 
constituent sample extract was injected on LC column. A steady ion 
response was obtained as a function of time since the analyte was 
infused at a constant rate. Any endogenous compound that elutes 
from the column which causes a variation in ESI response of the 
infused analyte was seen as suppression or enhancement in the 
(X: Concentration) weighing 
factor. The CC should have a correlation coefficient (r) of 0.99 or 
better. The acceptance criteria for each back-calculated standard 
concentration were±15% deviation from the nominal value except at 
LLOQ, which was set at±20%. 
Recovery 
The efficiency of cardiazol and IS extraction from human plasma was 
determined by comparing the responses of the analytes extracted 
from replicate QC samples (n=6) with those of neat standard 
solutions spiked in post-extracted plasma blank sample at 
equivalent concentrations by protein precipitation extraction 
method. Recovery of cardiazol was determined at LQC (3.00 ng/ml) 
and HQC (75.00 ng/ml) concentrations, whereas the recovery of IS 
was determined at a single concentration of 20 ng/ml. 
Matrix effect 
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response of the infused analyte. A separate experiment was 
performed with cardiazol and IS solutions, which were infused at a 
constant rate, and blank matrix sample injected through the LC. To 
evaluate matrix effect, different lots of human plasma were spiked 
with analyte concentration levels at LQC and HQC levels. According 
to guidelines, the acceptance criterion for each back-calculated 
concentration was±15% deviation from the nominal value. 
Precision and accuracy 
The intra-assay precision and accuracy were estimated by analyzing six 
replicates containing cardiazol at four different QC levels in human 
plasma. The four-level QC samples on four different runs were 
performed to assess the interassay precision. The acceptance criteria for 
each back-calculated standard concentration were 85-115% accuracy 
from the nominal value except at LLOQ, which was set at 80-120%. 
Stability experiments 
Stability tests were conducted to evaluate the stability of cardiazol in 
plasma samples under different conditions. 8 h bench top stability, 
processed samples stability (autosampler stability for 26 h at 10 °C), 
three cycles of freeze-thaw stability, 30 d of long-term stability at 
−80±10 °C were performed at LQC and HQC levels using six replicates 
at each level. Samples were considered stable if assay values’ 
acceptance criterion was of accuracy (i.e., 85-115% from fresh 
samples) and precision (i.e.,±15% relative standard deviation [RSD]). 
RESULTS AND DISCUSSION 
Cardiazol is original newly synthesized cardioprotective. That's why 
previously was no any bioanalytical method development for 
cardiazol. But aim of our work was also to develop rapid, sensitive, 
and highly selective liquid chromatography-tandem mass 
spectrometry method for cardiazol and improve method 
development for all derivatives of thiazole. 
In the present study, optimization and critical evaluation of mobile 
phase composition (gradient), flow rate, and analytical column were 
important to obtain a good resolution of peaks of interest from the 
endogenous components, which in turn affect reproducibility and 
sensitivity of the method. Selection of chromatographic conditions 
for the proposed method was optimized to suit the preclinical 
pharmacokinetic studies. To ease the sample preparation in 
microtubes and to reduce the usage of solvent, the plasma volume 
was kept low. Initial feasibility experiments of a various mixture(s) 
of solvents such as acetonitrile, methanol and formic acid along with 
altered flow rates (in the range of 0.1-0.6 ml/min) were performed to 
optimize an effective chromatographic resolution of cardiazol and IS. 
Various analytical columns were tested to obtained good and 
reproducible response within the short run time. The resolution of 
peaks was best achieved with Discovery C18, 50 × 2.1 mm, 5 μm 
column. Samples were chromatographed in a gradient mode (eluent A 
(acetonitrile-water–formic acid, 5: 95: 0.1 v/v), eluent B (acetonitrile–
formic acid, 100: 0.1 v/v)). The initial content of the eluent B of 8%, 
which increases linearly to 1.0 min to 100%, is maintained up to 1.5 
min and returned to the original 8% to 1.51 min. The mobile phase 
was delivered at a flow rate of 0.400 ml/min into the mass 
spectrometer ESI chamber. The injection volume was 300 μl.  
The purpose of sample extraction optimization is mainly to achieve 
high extraction recovery with negligible or low matrix effects to 
improve the sensitivity and reliability of LC-MS/MS analysis [6-11]. 
A poor extraction procedure decreases method robustness due to 
the presence of endogenous interference in the sample extracts, 
which are not efficiently cleaned up due to poor extraction 
procedure decreases the method robustness due to the endogenous 
interference in the sample extracts. With time-saving advantage and 
simplicity, the protein precipitation extraction method was chosen 
as an extraction method. The attained LLOQ was sufficient to 
quantify cardiazol in low-dose pharmacokinetic studies. 
Cardiazol eluted at ~2.15 min, respectively. During a direct infusion 
experiment, the mass spectra for cardiazol and IS revealed peaks at m/z 
391.08 and 406.100, respectively as protonated molecular ions, [M+H]+. 
Typical multiple reaction monitoring chromatograms of cardiazol and 
internal standard in dipotassium ethylenediaminetetraacetic acid human 




Fig. 2: Typical multiple reaction monitoring chromatograms of cardiazol (left) and internal standard (difenoconazole) (right) in 
dipotassium ethylenediaminetetraacetic acid human blank plasma 
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The total chromatographic run time was 2.5 min and the elution of 
cardiazol and IS (difenoconazole) occurred at ~2.15 and 1.98 min, 
respectively.  
Specificity 
Different lots of plasma were analysed to ensure that no endogenous 
interferences were present at the retention time of cardiazol LLOQ 
level samples along with plasma blank from the respective plasma 
lots were prepared and analysed (table 3). 
Linearity 
The calibration standard curves had a reliable reproducibility over the 
standard concentrations across the calibration range. The average 
regression (n=3) was found to be>0.99 for an analyte. 
  
Table 3: Results of specificity for cardiazol 
S. No. Enalapril 
STD BL LLOQ % Interference 
Area RT 
1 0 2031 2.15 NIL 
2 0 2033 2.14 NIL 
3 0 2039 2.15 NIL 
4 0 2029 2.14 NIL 
5 0 2038 2.14 NIL 
6 0 2032 2.14 NIL 
7 0 2030 2.15 NIL 
8 0 2042 2.15 NIL 
9 0 2029 2.15 NIL 
10 0 2031 2.15 NIL 
*
 
Fig. 3: The calibration curve of cardiazol in human plasma 
Average of triplicate injections, In all plasma blanks, the response at the retention time of cardiazol was less than 20% of LLOQ response and at the 
retention time of IS, the response was less than 5% of mean IS response in LLOQ.  
 
 
The calibration curve (fig. 3) (peak area ratio Vs Concentration) 
was linear over working range for cardiazol of 1 to 100.00 ng/ml 
with 7 point calibration used for quantification by linear 
regression, shown in fig. 3. The regression equation for the 
analysis was 
y=0.0141x+-0.00146 with coefficient of correction (r2) = 0.9985. 
Recovery 
The % mean recovery for cardiazol in LQC, MQC and HQC are listed in 
table 4. 
 
Table 4: The % mean recovery of cardiazol for LQC, MQC and HQC 
S. No. LQC MQC HQC 
1 2.97 28.4 76.6 
2 3.14 29.6 71.3 
3 3.10 31.5 70.6 
4 3.08 30.2 69.7 
5 3.13 30.7 71.3 
Mean 3.08 30.1 71.9 
SD 0.069 1.14 2.69 
% CV 2.2 3.8 3.7 
% Mean Recovery 102.8 100.3 95.9 
 
*
The % mean recovery for cardiazol in LQC, MQC and HQC was 102.8 
%, 100.3 % and 95.9 %. 
Intraday (within run) and Inter-day (between run) precision 
and accuracy 
Abbreviations: Lower quality control (LQC), middle-quality control 
(MQC), higher quality control (HQC)  
Each value is represented as a mean±SD of 5 observations (n=5), SD: 
Standard Deviation, RSD: Relative Standard Deviation, #Acceptance 
criteria<15 %. 
The within-run coefficients of variation ranged between 0.311 % 
and 0.601 % for cardiazol. The within-run percentages of nominal 
concentrations ranged between 99.80 % and 100.41 % for cardiazol. 
The between-run coefficients of variation ranged between 0.332 % 
and 0.615 % for cardiazol. The between-run percentages of nominal 
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concentrations ranged between 98.18 % and 101.21 % for cardiazol. Results are presented in table 5. 
  
Table 5: Intra-day and Inter-day precision data of cardiazol 
Day Intra-day precision Inter-day precision 
 Mean RSD % Mean RSD % 
1 99.80 0.378 101.21 0.332 
2 100.41 0.601 98.18 0.390 
3 100.23 0.311 100.13 0.615 
*Each value is represented as a mean±SD of observations, SD: Standard Deviation, RSD: Relative Standard Deviation, #Acceptance criteria<15 %. 
The assay values on both the occasions (intra-and inter-day) were found to be within the accepted limits. 
 
Table 6: Results of matrix effect of cardiazol 








% CV 11.9 
% Mean Recovery 109.7 
 
Matrix effect 
The lowest concentration with the RSD<20% was taken as LLOQ and 
was found to be 1.10 ng/ml for cardiazol. Results are presented in 
tables 6. 
*
The % accuracy of LLOQ samples prepared with the different biological 
matrix lots was found 109.7 %, which were found within the range of 
80.00-120.00 % for the seven different plasma lots. % CV for LLOQ 
samples was observed as 11.9 %, which are within 20.00% of the 
acceptance criteria. 
Abbreviations: Lower limit of quantification (LLOQ) 
Each value is represented as a mean±SD of 5 observations (n=5), SD: 
Standard Deviation, RSD: Relative Standard Deviation, #Acceptance 
criteria<20 %. 
Stability 
The predicted concentrations for cardiazol (3.00 ng/ml and 75.00 
ng/ml) deviated within±15% of the fresh sample concentrations in a 
battery of stability tests namely, in-injector (22 h), bench-top (7 h), 
and repeated four freeze/thaw cycles stability (table 7). 
  
Table 7: Stability data of cardiazol at QCs in human plasma 
Nominal concentration (ng/ml) Stability Stability data 
mean±SD °(n=6) Accuracy (%)• Precision (% CV) 
Cardiazol-3.00 0 h 3.10±0.43 99.6 2.24 
7 h (bench-Top) 3.01±0.37 99.6 2.14 
22 h (in-injector) 3.00±0.39 99.3 2.26 
3 FT cycles 3.09±0.41 99.9 2.16 
Cardiazol-75.00 0 h 75.2±0.39 99.8 2.67 
7 h (bench-Top) 75.4±0.21 99.9 2.31 
22 h (in-injector) 75.4±0.22 99.9 2.31 
3 FT cycles 75.5±0.31 99.1 3.06 
 °Back-calculated plasma concentrations; •Mean assayed concentration/mean assayed concentration at 0 h × 100. FT: Freeze-thaw, SD: Standard 
deviation, QC: Quality control, The results were found to be within the assay variability limits during the entire process. 
 
CONCLUSION 
A highly sensitive, specific, reproducible, rapid and high-throughput 
LC-MS/MS assay was developed and validated to quantify cardiazol in 
human plasma as per the regulatory guidelines. The present method 
involved a simple precipitation method of sample preparation, which 
gave consistent and reproducible recoveries. Acquired results 
demonstrate that the proposed strategy can be effortlessly and 
advantageously applied for routine examination of cardiazol in human 
plasma. The combination was taken up for developing a bioanalytical 
method development and validation so that further it would be useful 
for performing pharmacokinetic studies. 
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